Search Results - Haarberg, Sasha

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?

    Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials? by Van Tine, Brian A, Haarberg, Sasha

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy

    A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy by Hirbe, Angela C., Eulo, Vanessa, Moon, Chang I., Luo, Jingqin, Myles, Stephanie, Seetharam, Mahesh, Toeniskoetter, Jacqui, Kershner, Tammy, Haarberg, Sasha, Agulnik, Mark, Monga, Varun, Milhem, Mohammad, Parkes, Amanda, Robinson, Steven, Okuno, Scott, Attia, Steven, Van Tine, Brian A.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: